Latest News
Alert On Circulation Of Fake Coartem Tablets - Thursday, 28 December 2017 09:29
Warning On Homoeopathic Teething Tablets - Wednesday, 20 December 2017 15:04
Recall Of Rhino 7 Platinum 5000 Capsules - Wednesday, 20 December 2017 15:00
Recall Of Vancomycin Hydrochloride For Injection - Wednesday, 20 December 2017 14:44
Mislabeled Whole Foods Market Pb& J Parfait - Wednesday, 20 December 2017 14:34
Recall Of Man Of Steel 1 And 2 - Wednesday, 20 December 2017 14:22
Recall Of Lots Of Diocto Liquid And Diocto Syrup - Wednesday, 20 December 2017 14:08


  1. AVASTIN is a drug that was approved for the treatment of breast cancer. Investigations by the US FDA have shown that patients on Avastin experienced high blood pressure and fatigue. A follow up investigation by the manufacturer, Roche also revealed that the drug does not significantly prolong the lives of patients when compared to chemotherapy. The US FDA has proposed a ban of the drug due to the observed serious side effects and its failure to slow tumor growth or help breast cancer patients. In view of the current findings on Avastin, NAFDAC is closely monitoring the safety/efficacy of this drug with a view to determining appropriate regulatory action. NAFDAC also wishes to advise all healthcare practitioners to closely monitor the use of Avastin and report any observed adverse effects to the National Pharmacovigilance Centre, NAFDAC Abuja.



Contact Us from Mon - Friday: 08:00-16:00 GMT+1

Write Us:

NAFDAC Corporate Headquarters,

Plot 2032, Olusegun, Obasanjo Way,

Zone 7, Wuse, Abuja, Nigeria


Lagos Operation Office:

Plot 1, Industrial Estate, Lagos- Oshodi Apapa Express Way, Isolo, Lagos, Nigeria







For Enquiries:

Call: +234(0)-1-4609750












For Complaints:

Call: +234(0)909-763-0506


Or Send Us a Complaint










Contact Other NAFDAC Offices Nationwide